J&J Remicade Hepatotoxicity Warning Is Subject Of “Dear Doctor” Letter
Executive Summary
Johnson & Johnson is alerting prescribers to a new hepatotoxicity warning in Remicade labeling via a "Dear Doctor" letter
You may also be interested in...
J&J Remicade Labeling Adds TNF-Inhibitor Malignancy Warning
Centocor is revising Remicade (infliximab) labeling to include a malignancy warning similar to that of other TNF-inhibitors
J&J’s Remicade Adds Hematologic, Neurologic Warnings To Label
Johnson & Johnson's TNF-inhibitor Remicade has added warnings for hematologic and neurologic events to its label
Enbrel Cleared For Ankylosing Spondylitis; Heart Failure Precaution Added
Amgen/Wyeth is awaiting approval for two additional Enbrel indications following FDA clearance of the TNF-inhibitor for ankylosing spondylitis July 24